Back To Back Trial Failures: Analyst Weighs In On Travere Therapeutics' Prospects, Challenges
Portfolio Pulse from Vandana Singh
William Blair downgraded Travere Therapeutics Inc (NASDAQ:TVTX) to Market Perform after the company's Phase 3 PROTECT Study of Filspari did not meet its two-year endpoint. The analysts believe that the trajectory of Filspari will be the primary catalyst influencing stock performance in the short term. TVTX shares are down 41.03 at $7.59 on the last check Thursday.
September 21, 2023 | 7:01 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Travere Therapeutics' stock was downgraded by William Blair due to a failed Phase 3 trial. The stock price has fallen significantly.
The downgrade by William Blair is a direct result of the failed Phase 3 trial. This negative news is likely to have a significant impact on the stock price in the short term.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100